Search by Drug Name or NDC
NDC 00008-1123-12 Duavee 20; .45 mg/1; mg/1 Details
Duavee 20; .45 mg/1; mg/1
Duavee is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.. The primary component is BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED.
MedlinePlus Drug Summary
Estrogen and bazedoxifene tablets are used to treat hot flashes (sudden feelings of warmth, especially in the face, neck, and chest) in women who are experiencing menopause (stage of life when menstrual periods become less frequent and stop and women may experience other symptoms and body changes). Estrogen and bazedoxifene tablets are also used to prevent osteoporosis (condition in which the bones become thin and weak and break easily) in women who have undergone menopause. Estrogen is in a class of medications called hormones and bazedoxifene is in a class of medications called estrogen agonist–antagonists. Estrogen works by replacing estrogen that is normally produced by the body. Bazedoxifene is used to block the action of estrogen on the lining of the uterus, decreasing the risk of overgrowth that may lead to cancer.
Related Packages: 00008-1123-12Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Estrogen and Bazedoxifene
Product Information
| NDC | 00008-1123 |
|---|---|
| Product ID | 0008-1123_4446d2d6-3c89-4815-af03-bebcd1237cbd |
| Associated GPIs | 24995002100330 |
| GCN Sequence Number | 071889 |
| GCN Sequence Number Description | estrogens,conj/bazedoxifene TABLET 0.45-20 MG ORAL |
| HIC3 | G1G |
| HIC3 Description | ESTROGEN-SELECTIVE ESTROGEN RECEPTOR MOD(SERM)COMB |
| GCN | 35909 |
| HICL Sequence Number | 040855 |
| HICL Sequence Number Description | ESTROGENS, CONJUGATED/BAZEDOXIFENE ACETATE |
| Brand/Generic | Brand |
| Proprietary Name | Duavee |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | conjugated estrogens/bazedoxifene |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 20; .45 |
| Active Ingredient Units | mg/1; mg/1 |
| Substance Name | BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED |
| Labeler Name | Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. |
| Pharmaceutical Class | Estrogen Agonist/Antagonist [EPC], Estrogen Receptor Agonists [MoA], Estrogen [EPC], Estrogens, Conjugated (USP) [CS], Selective Estrogen Receptor Modulators [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA022247 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00008-1123-12 (00008112312)
| NDC Package Code | 0008-1123-12 |
|---|---|
| Billing NDC | 00008112312 |
| Package | 1 POUCH in 1 CARTON (0008-1123-12) / 2 BLISTER PACK in 1 POUCH / 15 TABLET, FILM COATED in 1 BLISTER PACK |
| Marketing Start Date | 2013-10-03 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 6.29835 |
| Pricing Unit | EA |
| Effective Date | 2024-01-01 |
| NDC Description | DUAVEE 0.45-20 MG TABLET |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4 |
| Classification for Rate Setting | B |
| As of Date | 2024-02-21 |